TABLE 1.
Antimicrobial efficacy of aPDT with SAPYR, SA-PN-05, and of CHX toward A. naeslundii, S. mutans, and E. coli biofilms.
| Incubation period (min) | UC | SAPYR 50 μM |
SAPYR 100 μM |
SAPYR 500 μM |
SA-PN-05 50 μM |
SA-PN-05 100 μM |
SA-PN-05 500 μM |
CHX 0.2% | |||||||
| L+ | L+ | L− | L+ | L− | L+ | L− | L+ | L− | L+ | L− | L+ | L− | L− | ||
| A. naeslundii | 5 | 0.2 | 2.5 | 0.1 | 3 | 0.2 | 5.4 | 0.4 | 1.6 | 4.8 | 0.8 | ≥6.0 | 2.4 | ≥6.0 | 4.7 |
| 10 | – | 1.0 | – | 1.4 | – | 2.3 | – | 1.0 | 2.4 | 1.4 | ≥6.0 | 2.2 | ≥6.0 | ≥6.0 | |
| 20 | 0.2 | 1.3 | – | 2.0 | – | 4.3 | – | 1.2 | 1.9 | 0.9 | ≥6.0 | 1.7 | ≥6.0 | ≥6.0 | |
| 30 | 0.1 | 4.4 | 0.1 | 4.7 | – | ≥6.0 | 0.3 | 0.2 | 4.4 | – | ≥6.0 | 1.6 | ≥6.0 | ≥6.0 | |
| S. mutans | 5 | – | ≥6.0 | 0.1 | 5.3 | – | ≥6.0 | 0.71 | 0.8 | 1.8 | 0.9 | 4.8 | 4.8 | ≥6.0 | ≥6.0 |
| 10 | 0.3 | ≥6.0 | 1.5 | ≥6.0 | 1.4 | ≥6.0 | 2.0 | 1.8 | 2.2 | 1.5 | 4.1 | 4.6 | ≥6.0 | ≥6.0 | |
| 20 | 0.3 | ≥6.0 | 0.4 | ≥6.0 | 0.3 | ≥6.0 | 2.3 | 1.4 | 1.8 | 1.9 | 3.8 | 3.8 | ≥6.0 | ≥6.0 | |
| 30 | – | 5.7 | – | 5.5 | 0.2 | ≥6.0 | 0.9 | 1.8 | 1.5 | 1.9 | 3.8 | ≥6.0 | ≥6.0 | ≥6.0 | |
| E. coli | 5 | 0.7 | 2.6 | 0.1 | 2.4 | 0.2 | 2.9 | 0.4 | 0.9 | 0.1 | 0.6 | 0.6 | 1.5 | 3.7 | ≥6.0 |
| 10 | 0.7 | 2.2 | 0.1 | 2.5 | 0.1 | 2.5 | 0.4 | 1.5 | 0.3 | 2.0 | 0.7 | 1.8 | 3.8 | ≥6.0 | |
| 20 | 0.2 | 2.1 | – | 2.3 | – | 2.6 | – | 1.4 | 0.6 | 1.4 | 1.2 | 3.5 | ≥6.0 | ≥6.0 | |
| 30 | 0.6 | 2.2 | 0.1 | 2.3 | 0.2 | 2.7 | – | 2.1 | 0.6 | 1.6 | 1.2 | 3.1 | 4.3 | ≥6.0 | |
Log10 reduction of SAPYR, SA-PN-05 and CHX against A. naeslundii, S. mutans, and E. coli for all incubation periods applied as compared to untreated, not irradiated controls (UC L−). L− represents dark groups; L+ represents irradiated groups. – indicates no step reduction of CFU.